Andrea Forschner (A Forschner)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 32

Top Topics

Top Venues

Journal for immunotherapy of cancer

Cancer immunology, immunotherapy : CII

Diagnostics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Daniela Lenders, Irina Bonzheim, Matthias Hahn, Maximilian Gassenmaier, Valentin Aebischer, Andrea Forschner, Max Matthias Lenders, Lukas Flatz, Stephan Forchhammer
An Automated Real-Time PCR Assay versus Next-Generation Sequencing in the Detection of BRAF V600 Mutations in Melanoma Tissue Samples. Diagnostics (Basel, Switzerland) 14 (15) (2024)
A Gawaz, I Wolff, L Nanz, Lukas Flatz, Andrea Forschner
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Henner Stege, Sara Schneider, Andrea Forschner, Thomas Eigentler, Dorothée Nashan, Svea Huening, Saskia Lehr, Frank Meiss, Martin Kaatz, Robert Kuchen, Katharina C Kaehler, Maximilian Haist, Stephan Grabbe, Jutta Huebner, Carmen Loquai
Second opinion and self-efficacy in German skin cancer patients. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2024)
A Gawaz, I Wolff, L Nanz, Lukas Flatz, Andrea Forschner
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Daniela Lenders, Irina Bonzheim, Matthias Hahn, Maximilian Gassenmaier, Valentin Aebischer, Andrea Forschner, Max Matthias Lenders, Lukas Flatz, Stephan Forchhammer
An Automated Real-Time PCR Assay versus Next-Generation Sequencing in the Detection of BRAF V600 Mutations in Melanoma Tissue Samples. Diagnostics (Basel, Switzerland) 14 (15) (2024)
A Gawaz, I Wolff, L Nanz, Lukas Flatz, Andrea Forschner
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
A Gawaz, I Wolff, L Nanz, Lukas Flatz, Andrea Forschner
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Andrea Forschner, Lena Nanz, Yves Maczey-Leber, Teresa Amaral, Lukas Flatz, Ulrike Leiter
Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition. International journal of cancer (2024)
Maximilian Haist, Henner Stege, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Friedegund Meier, Peter Mohr, Katharina C Kähler, Michael Weichenthal, Axel Hauschild, Dirk Schadendorf, Selma Ugurel, Georg Lodde, Lisa Zimmer, Ralf Gutzmer, Dirk Debus, Bastian Schilling, Alexander Kreuter, Jens Ulrich, Frank Meiss, Rudolf Herbst, Andrea Forschner, Ulrike Leiter, Claudia Pfoehler, Martin Kaatz, Fabian Ziller, Jessica C Hassel, Michael Tronnier, Michael Sachse, Edgar Dippel, Patrick Terheyden, Carola Berking, Markus V Heppt, Felix Kiecker, Sebastian Haferkamp, Christoffer Gebhardt, Jan Christoph Simon, Stephan Grabbe, Carmen Loquai
Treatment management for BRAF -mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG. Journal for immunotherapy of cancer 11 (9) (2023)
Christian Philipp Reinert, Cecilia Zhang, Matthias Weissinger, Jonas Vogel, Andrea Forschner, Konstantin Nikolaou, Christian la Fougère, Ferdinand Seith
Whole-Body Magnetic Resonance Imaging (MRI) for Staging Melanoma Patients in Direct Comparison to Computed Tomography (CT): Results from a Prospective Positron Emission Tomography (PET)/CT and PET/MRI Study. Diagnostics (Basel, Switzerland) 13 (11) (2023)
Manuel Kolb, Andrea Forschner, Christoph Artzner, Gerd Grözinger, Ines Said, Helmut Dittmann, Ferdinand Seith
Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study. Cancers 15 (20) (2023)
Manuel Lauinger, Daniel Christen, Rhena F U Klar, Carole Roubaty, Christoph E Heilig, Michael Stumpe, Jennifer J Knox, Nikolina Radulovich, Laura Tamblyn, Irene Y Xie, Peter Horak, Andrea Forschner, Michael Bitzer, Uwe A Wittel, Melanie Börries, Claudia R Ball, Christoph Heining, Hanno Glimm, Martina Fröhlich, Daniel Hübschmann, Steven Gallinger, Ralph Fritsch, Stefan Fröhling, Grainne M O'Kane, Joern Dengjel, Tilman Brummer
BRAF Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability. Science advances 9 (35) (2023)
Cindy Franklin, Peter Mohr, Leonie Bluhm, Friedegund Meier, Marlene Garzarolli, Michael Weichenthal, Katharina Kähler, Imke Grimmelmann, Ralf Gutzmer, Jochen Utikal, Patrick Terheyden, Rudolf Herbst, Sebastian Haferkamp, Claudia Pfoehler, Andrea Forschner, Ulrike Leiter, Fabian Ziller, Frank Meiss, Jens Ulrich, Alexander Kreuter, Christoffer Gebhardt, Julia Welzel, Bastian Schilling, Martin Kaatz, Karin Scharfetter-Kochanek, Edgar Dippel, Dorothee Nashan, Michael Sachse, Carsten Weishaupt, Harald Löffler, Thilo Gambichler, Carmen Loquai, Lucie Heinzerling, Stephan Grabbe, Dirk Debus, Gaston Schley, Jessica C Hassel, Gerhard Weyandt, Maike Trommer, Georg Lodde, Jan-Malte Placke, Lisa Zimmer, Elisabeth Livingstone, Jürgen Christian Becker, Susanne Horn, Dirk Schadendorf, Selma Ugurel
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. Journal for immunotherapy of cancer 11 (4) (2023)
Cindy Franklin, Peter Mohr, Leonie Bluhm, Imke Grimmelmann, Ralf Gutzmer, Friedegund Meier, Marlene Garzarolli, Michael Weichenthal, Claudia Pfoehler, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Jens Ulrich, Dirk Debus, Sebastian Haferkamp, Martin Kaatz, Andrea Forschner, Ulrike Leiter, Dorothee Nashan, Alexander Kreuter, Michael Sachse, Julia Welzel, Lucie Heinzerling, Frank Meiss, Carsten Weishaupt, Thilo Gambichler, Gerhard Weyandt, Edgar Dippel, Kerstin Schatton, Eren Celik, Maike Trommer, Iris Helfrich, Alexander Roesch, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Susanne Horn, Selma Ugurel
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. Journal for immunotherapy of cancer 10 (6) (2022)
Julia Eckardt, Christopher Schroeder, Peter Martus, Sorin Armeanu-Ebinger, Olga Kelemen, Axel Gschwind, Irina Bonzheim, Thomas Eigentler, Teresa Amaral, Stephan Ossowski, Olaf Rieß, Lukas Flatz, Claus Garbe, Andrea Forschner
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. Journal of cancer research and clinical oncology (2022)
Andrea Forschner, Heike Niessner, Tobias Sinnberg, Thomas Kurt Eigentler, Teresa Amaral, Ferdinand Seith, Claus Garbe, Saskia Biskup, Florian Battke
Zirkulierende Tumor-DNA (ctDNA) bei der Entdeckung von Rezidiven bei Melanompatienten mit adjuvanter Anti-PD-1-Therapie. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20 (6) (2022)
Henner Stege, Sara Schneider, Andrea Forschner, Thomas Kurt Eigentler, Dorothée Nashan, Svea Huening, Frank Meiss, Saskia Lehr, Martin Kaatz, Robert Kuchen, Katharina C Kaehler, Maximilian Haist, Jutta Huebner, Carmen Loquai
eHealth Literacy in German Skin Cancer Patients. International journal of environmental research and public health 19 (14) (2022)
Nikolaus Benjamin Wagner, Max M Lenders, Kathrin Kühl, Lydia Reinhardt, Fiona André, Milena Dudda, Natalie Ring, Chiara Ebel, Ramon Stäger, Caroline Zellweger, Roland Lang, Michael Paar, Philipp Gussek, Georg Richtig, Suzan H Stürmer, Susanne Kimeswenger, Angela Oellinger, Andrea Forschner, Ulrike Leiter, Benjamin Weide, Maximilian Gassenmaier, Amadeus Schraag, Bernhard Klumpp, Wolfram Hoetzenecker, Carola Berking, Erika Richtig, Mirjana Ziemer, Johanna Mangana, Patrick Terheyden, Carmen Loquai, Van Anh Nguyen, Christoffer Gebhardt, Friedegund Meier, Stefan Diem, Antonio Cozzio, Lukas Flatz, Martin Röcken, Claus Garbe, Thomas K Eigentler
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. Journal for immunotherapy of cancer 9 (5) (2022)
Thomas Küstner, Jonas Vogel, Tobias Hepp, Andrea Forschner, Christina Pfannenberg, Holger Schmidt, Nina F Schwenzer, Konstantin Nikolaou, Christian la Fougère, Ferdinand Seith
Development of a Hybrid-Imaging-Based Prognostic Index for Metastasized-Melanoma Patients in Whole-Body 18F-FDG PET/CT and PET/MRI Data. Diagnostics (Basel, Switzerland) 12 (9) (2022)
Marcus Wölffer, Florian Battke, Martin Schulze, Magdalena Feldhahn, Lukas Flatz, Peter Martus, Andrea Forschner
Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma. Cancers 14 (2) (2022)
Jyoti Chauhan, Sathyaraj Aasaithambi, Ivan Marquez-Rodas, Luigi Formisano, Sophie Papa, Nicolas Meyer, Andrea Forschner, Guy Faust, Mike Lau, Alexandros Sagkriotis
Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. JMIR cancer 8 (2) (2022)
Timo E Schank, Andrea Forschner, Michael Max Sachse, Antonia Dimitrakopoulou-Strauss, Christos Sachpekidis, Albrecht Stenzinger, Anna-Lena Volckmar, Alexander Enk, Jessica C Hassel
Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers 13 (11) (2021)
Dieter Leupold, Lutz Pfeifer, Maja Hofmann, Andrea Forschner, Gerd Wessler, Holger Haenssle
From Melanocytes to Melanoma Cells: Characterization of the Malignant Transformation by Four Distinctly Different Melanin Fluorescence Spectra (Review). International journal of molecular sciences 22 (10) (2021)
Marisa Schmitt, Tobias Sinnberg, Heike Niessner, Andrea Forschner, Claus Garbe, Boris Macek, Nicolas C Nalpas
Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy. Cancers 13 (21) (2021)
Henner Stege, Maximilian Haist, Michael Schultheis, Maria Isabel Fleischer, Peter Mohr, Friedegund Meier, Dirk Schadendorf, Selma Ugurel, Elisabeth Livingstone, Lisa Zimmer, Rudolf Herbst, Claudia Pföhler, Katharina Kähler, Michael Weichenthal, Patrick Terheyden, Dorothée Nashan, Dirk Debus, Martin Kaatz, Fabian Ziller, Sebastian Haferkamp, Andrea Forschner, Ulrike Leiter, Alexander Kreuter, Jens Ulrich, Johannes Kleemann, Fabienne Bradfisch, Stephan Grabbe, Carmen Loquai
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study. Cancers 13 (10) (2021)
Ferdinand Seith, Andrea Forschner, Benjamin Weide, Brigitte Gückel, Martin Schwartz, Johannes Schwenck, Ahmed E Othman, Matthias Fenchel, Claus Garbe, Konstantin Nikolaou, Nina Schwenzer, Christian la Fougère, Christina Pfannenberg
Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy? Journal for immunotherapy of cancer 8 (2) (2021)
Lina María Serna Higuita, Teresa Amaral, Andrea Forschner, Ulrike Leiter, Lukas Flatz, Olivia Seeber, Ioannis Thomas, Claus Garbe, Thomas Kurt Eigentler, Peter Martus
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers 13 (23) (2021)
Georg Lodde, Andrea Forschner, Jessica Hassel, Lena M Wulfken, Friedegund Meier, Peter Mohr, Katharina Kähler, Bastian Schilling, Carmen Loquai, Carola Berking, Svea Hüning, Kerstin Schatton, Christoffer Gebhardt, Julia Eckardt, Ralf Gutzmer, Lydia Reinhardt, Valerie Glutsch, Ulrike Nikfarjam, Michael Erdmann, Andreas Stang, Bernd Kowall, Alexander Roesch, Selma Ugurel, Lisa Zimmer, Dirk Schadendorf, Elisabeth Livingstone
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. Cancers 13 (10) (2021)
Lisa Wiens, Norbert Schäffeler, Thomas Eigentler, Claus Garbe, Andrea Forschner
Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study. Cancers 13 (11) (2021)
Susann-Cathrin Olthof, Andrea Forschner, Peter Martus, Claus Garbe, Konstantin Nikolaou, Christian Peter la Fougère, Brigitte Gückel, Werner Vach, Christina Pfannenberg
Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach. European journal of nuclear medicine and molecular imaging 47 (10) (2020)
Andrea Forschner, Stephanie Weißgraeber, Dirk Hadaschik, Martin Schulze, Maria Kopp, Sabine Kelkenberg, Tobias Sinnberg, Claus Garbe, Saskia Biskup, Florian Battke
Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study. OncoTargets and therapy 13 (2020)
Andrea Forschner, Florian Battke, Dirk Hadaschik, Martin Schulze, Stephanie Weißgraeber, Chung-Ting Han, Maria Kopp, Maximilian Frick, Bernhard Klumpp, Nicola Tietze, Teresa Amaral, Peter Martus, Tobias Sinnberg, Thomas Eigentler, Ulrike Keim, Claus Garbe, Dennis Döcker, Saskia Biskup
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. Journal for immunotherapy of cancer 7 (1) (2019)